Bill > HR4581

This bill, known as the 340B PATIENTS Act of 2025, aims to clarify and strengthen the 340B Drug Discount Program, which allows certain healthcare providers (called "covered entities") to purchase prescription drugs at significantly reduced prices. The bill reinforces that drug manufacturers must offer discounted pricing to covered entities regardless of how or where the drugs are dispensed, including through contract pharmacies. It specifically addresses issues surrounding contract pharmacies, which are crucial for helping healthcare providers access specialty drugs that treat chronic or life-threatening conditions. The legislation prohibits drug manufacturers from placing unreasonable conditions on drug purchases, such as limiting drug delivery mechanisms or requiring excessive reporting. Additionally, the bill establishes penalties for manufacturers who violate these requirements, with potential civil monetary penalties up to $2 million per day for intentional violations. The bill's broader purpose is to help healthcare providers stretch their resources, expand patient care, and ensure more comprehensive medical services, particularly for underserved communities. By clarifying the original 340B program's intent and preventing manufacturer restrictions, the legislation seeks to protect and enhance access to affordable medications for patients served by nonprofit hospitals, clinics, and health centers.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/4581/all-info